323 related articles for article (PubMed ID: 29592892)
1. Gene dosage effect of CUX1 in a murine model disrupts HSC homeostasis and controls the severity and mortality of MDS.
An N; Khan S; Imgruet MK; Gurbuxani SK; Konecki SN; Burgess MR; McNerney ME
Blood; 2018 Jun; 131(24):2682-2697. PubMed ID: 29592892
[TBL] [Abstract][Full Text] [Related]
2. CUX1 is a haploinsufficient tumor suppressor gene on chromosome 7 frequently inactivated in acute myeloid leukemia.
McNerney ME; Brown CD; Wang X; Bartom ET; Karmakar S; Bandlamudi C; Yu S; Ko J; Sandall BP; Stricker T; Anastasi J; Grossman RL; Cunningham JM; Le Beau MM; White KP
Blood; 2013 Feb; 121(6):975-83. PubMed ID: 23212519
[TBL] [Abstract][Full Text] [Related]
3. Oncogenic RAS promotes leukemic transformation of CUX1-deficient cells.
An N; Khan S; Imgruet MK; Jueng L; Gurbuxani S; McNerney ME
Oncogene; 2023 Mar; 42(12):881-893. PubMed ID: 36725889
[TBL] [Abstract][Full Text] [Related]
4. The significance of CUX1 and chromosome 7 in myeloid malignancies.
Jotte MRM; McNerney ME
Curr Opin Hematol; 2022 Mar; 29(2):92-102. PubMed ID: 35084368
[TBL] [Abstract][Full Text] [Related]
5. Molecular bases of myelodysplastic syndromes: lessons from animal models.
Komeno Y; Kitaura J; Kitamura T
J Cell Physiol; 2009 Jun; 219(3):529-34. PubMed ID: 19259975
[TBL] [Abstract][Full Text] [Related]
6. Inactivating CUX1 mutations promote tumorigenesis.
Wong CC; Martincorena I; Rust AG; Rashid M; Alifrangis C; Alexandrov LB; Tiffen JC; Kober C; ; Green AR; Massie CE; Nangalia J; Lempidaki S; Döhner H; Döhner K; Bray SJ; McDermott U; Papaemmanuil E; Campbell PJ; Adams DJ
Nat Genet; 2014 Jan; 46(1):33-8. PubMed ID: 24316979
[TBL] [Abstract][Full Text] [Related]
7. Distinct clinical and biological implications of
Aly M; Ramdzan ZM; Nagata Y; Balasubramanian SK; Hosono N; Makishima H; Visconte V; Kuzmanovic T; Adema V; Nazha A; Przychodzen BP; Kerr CM; Sekeres MA; Abazeed ME; Nepveu A; Maciejewski JP
Blood Adv; 2019 Jul; 3(14):2164-2178. PubMed ID: 31320321
[TBL] [Abstract][Full Text] [Related]
8. Loss of Asxl1 leads to myelodysplastic syndrome-like disease in mice.
Wang J; Li Z; He Y; Pan F; Chen S; Rhodes S; Nguyen L; Yuan J; Jiang L; Yang X; Weeks O; Liu Z; Zhou J; Ni H; Cai CL; Xu M; Yang FC
Blood; 2014 Jan; 123(4):541-53. PubMed ID: 24255920
[TBL] [Abstract][Full Text] [Related]
9. Loss of a 7q gene, CUX1, disrupts epigenetically driven DNA repair and drives therapy-related myeloid neoplasms.
Imgruet MK; Lutze J; An N; Hu B; Khan S; Kurkewich J; Martinez TC; Wolfgeher D; Gurbuxani SK; Kron SJ; McNerney ME
Blood; 2021 Sep; 138(9):790-805. PubMed ID: 34473231
[TBL] [Abstract][Full Text] [Related]
10.
Tara S; Isshiki Y; Nakajima-Takagi Y; Oshima M; Aoyama K; Tanaka T; Shinoda D; Koide S; Saraya A; Miyagi S; Manabe I; Matsui H; Koseki H; Bardwell VJ; Iwama A
Blood; 2018 Dec; 132(23):2470-2483. PubMed ID: 30228234
[No Abstract] [Full Text] [Related]
11. Architectural and functional heterogeneity of hematopoietic stem/progenitor cells in non-del(5q) myelodysplastic syndromes.
Chesnais V; Arcangeli ML; Delette C; Rousseau A; Guermouche H; Lefevre C; Bondu S; Diop M; Cheok M; Chapuis N; Legros L; Raynaud S; Willems L; Bouscary D; Lauret E; Bernard OA; Kosmider O; Pflumio F; Fontenay M
Blood; 2017 Jan; 129(4):484-496. PubMed ID: 27856460
[TBL] [Abstract][Full Text] [Related]
12. [Monosomy 7: recent progress].
Inaba T; Nagamachi A
Rinsho Ketsueki; 2019; 60(9):1020-1026. PubMed ID: 31597823
[TBL] [Abstract][Full Text] [Related]
13. Deficiency and haploinsufficiency of histone macroH2A1.1 in mice recapitulate hematopoietic defects of human myelodysplastic syndrome.
Bereshchenko O; Lo Re O; Nikulenkov F; Flamini S; Kotaskova J; Mazza T; Le Pannérer MM; Buschbeck M; Giallongo C; Palumbo G; Li Volti G; Pazienza V; Cervinek L; Riccardi C; Krejci L; Pospisilova S; Stewart AF; Vinciguerra M
Clin Epigenetics; 2019 Aug; 11(1):121. PubMed ID: 31439048
[TBL] [Abstract][Full Text] [Related]
14. Clinically Significant CUX1 Mutations Are Frequently Subclonal and Common in Myeloid Disorders With a High Number of Co-mutated Genes and Dysplastic Features.
Dermawan JK; Wensel C; Visconte V; Maciejewski JP; Cook JR; Bosler DS
Am J Clin Pathol; 2022 Apr; 157(4):586-594. PubMed ID: 34661647
[TBL] [Abstract][Full Text] [Related]
15. Aging, hematopoiesis, and the myelodysplastic syndromes.
Chung SS; Park CY
Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):73-78. PubMed ID: 29222239
[TBL] [Abstract][Full Text] [Related]
16. 5G2 mutant mice model loss of a commonly deleted segment of chromosome 7q22 in myeloid malignancies.
Wong JC; Weinfurtner KM; Westover T; Kim J; Lebish EJ; Del Pilar Alzamora M; Huang BJ; Walsh M; Abdelhamed S; Ma J; Klco JM; Shannon K
Leukemia; 2024 May; 38(5):1182-1186. PubMed ID: 38443608
[TBL] [Abstract][Full Text] [Related]
17. The Apc(min) mouse has altered hematopoietic stem cell function and provides a model for MPD/MDS.
Lane SW; Sykes SM; Al-Shahrour F; Shterental S; Paktinat M; Lo Celso C; Jesneck JL; Ebert BL; Williams DA; Gilliland DG
Blood; 2010 Apr; 115(17):3489-97. PubMed ID: 20197553
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic discovery for marrow failure with MDS predisposition using pluripotent stem cells.
Ruiz-Gutierrez M; Bölükbaşı ÖV; Alexe G; Kotini AG; Ballotti K; Joyce CE; Russell DW; Stegmaier K; Myers K; Novina CD; Papapetrou EP; Shimamura A
JCI Insight; 2019 Apr; 5(12):. PubMed ID: 31039138
[TBL] [Abstract][Full Text] [Related]
19.
Muench DE; Ferchen K; Velu CS; Pradhan K; Chetal K; Chen X; Weirauch MT; Colmenares C; Verma A; Salomonis N; Grimes HL
Blood; 2018 Nov; 132(21):e24-e34. PubMed ID: 30249787
[TBL] [Abstract][Full Text] [Related]
20. RAS transformation requires CUX1-dependent repair of oxidative DNA damage.
Ramdzan ZM; Vadnais C; Pal R; Vandal G; Cadieux C; Leduy L; Davoudi S; Hulea L; Yao L; Karnezis AN; Paquet M; Dankort D; Nepveu A
PLoS Biol; 2014 Mar; 12(3):e1001807. PubMed ID: 24618719
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
